LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR
WASHINGTON--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.